title: Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status in ovarian cancer.
abstract: Summary
  
  
  OBJECTIVE
  Ovarian cancer is the most deadly of all gynecologic malignancies, due in part to the diagnosis at an advanced stage caused by the deficiency of specific marks and symptoms, by the absence of reliable tests for screening, and by early detection.
  
  
  METHODS
  Insulin-like growth factor-I (IGF-I) is known to be involved in the development and promotion of diverse examples of solid tumors including ovarian cancer. IGF-I levels in local tissue are subject to both endocrine and paracrine/autocrine regulation.
  
  
  RESULTS
  Most patients will react initially to treatment, but almost 70% of them will have a recurrence. Consequently, new therapeutic modalities are urgently required to overcome chemoresistance observed in ovarian cancer patients. IGF-1R expression was evaluated immunohistochemically in tissue microarray blocks constructed from 1,200 ovarian cancer samples collected from three medical institutions.
  
  
  CONCLUSIONS
  Evidence accumulates suggesting that the insulin/insulin growth factor (IGF) pathways could play a good therapeutic target in various cancers, including ovarian cancer.
authors.forename: L Q
authors.initials: LQ
authors.lastname: Wang
authors.forename: W D
authors.initials: WD
authors.lastname: Zhao
authors.forename: X J
authors.initials: XJ
authors.lastname: Jiao
authors.forename: D L
authors.initials: DL
authors.lastname: Du
authors.forename: Y S
authors.initials: YS
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018269:Carcinoma, Endometrioid / Q000378:metabolism* / Q000473:pathology; D000077216:Carcinoma, Ovarian Epithelial; D018282:Cystadenocarcinoma, Mucinous / Q000378:metabolism* / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D017526:Receptor, IGF Type 1; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human